Stocks/DRTS/Filings & Earnings

DRTS SEC Filings, Earnings & Splits

Key events from SEC filings, earnings beat/miss history, stock split records, and share float data for DRTS.

What are DRTS's recent SEC filings?

6-K · OtherNov 19, 2026

Alpha Tau Medical Ltd. furnished a Form 6-K containing a press release announcing its third quarter 2026 financial results and providing a corporate update.

View full filing details →
6-K · OtherNov 16, 2026

Alpha Tau Medical announced positive interim results from its U.S. Alpha DaRT recurrent glioblastoma trial, reporting that all treated patients are alive with median survival not reached, 100% objective response rate, and no unanticipated serious adverse events in the first six evaluable patients.

View full filing details →
6-K · OtherNov 16, 2026

Alpha Tau Medical Ltd. furnished a Form 6-K disclosing that it held an investor call on November 16, 2026 to discuss new results from its REGAIN trial, with the accompanying investor presentation furnished as Exhibit 99.1.

View full filing details →
6-K · OtherNov 12, 2026

Alpha Tau Medical announced it will host an investor call to review new data from the Alpha DaRT Recurrent Glioblastoma REGAIN Trial. The announcement was made via a press release attached to a Form 6-K filing.

View full filing details →
6-K · OtherOct 29, 2026

Alpha Tau Medical Ltd. announced its inclusion in the flagship TA-90 and TA-125 indices of the Tel Aviv Stock Exchange, effective October 29, 2026.

View full filing details →
6-K · Material AgreementOct 22, 2026

Alpha Tau Medical Ltd. announced it signed a Memorandum of Understanding (MOU) with Samsung Medical Center to explore a clinical trial of its Alpha DaRT technology for pancreatic cancer patients in Korea.

View full filing details →
6-K · Fda ApprovalOct 19, 2026

Alpha Tau Medical announced FDA approval to expand its U.S. recurrent glioblastoma REGAIN trial for the Alpha DaRT technology, with new trial data to be presented at the SNO 2026 Annual Meeting.

View full filing details →
6-K · Fda ApprovalAug 31, 2026

Alpha Tau Medical Ltd. completed patient enrollment in its multicenter IMPACT pancreatic cancer pilot study of Alpha DaRT, indicating strong demand and multiple expansions.

View full filing details →

Has DRTS ever done a stock split?

No stock splits are recorded for DRTS.

What is DRTS's share float?

Public Float
$87.8M
Shares Outstanding
$88.0M
Free Float %
9981.5%

Get Real-Time DRTS Intelligence

SEPT X-Ray combines SEC filings with price targets, support/resistance levels, and smart money tracking — updated every 30 minutes.

Try SEPT X-Ray Free

More DRTS Research

DRTS FundamentalsDRTS AnalysisSEPT Academy
Share:XRedditFacebookLinkedIn
© SEPT Investing. Filing summaries are extracted automatically from SEC filings and may contain errors. Always verify with official SEC EDGAR filings. Trading involves risk.